文献速递骨软组织肉瘤与黑色素瘤

高危可切除黑色素瘤新辅助双免疫检查点抑制剂与抗PD1治疗的汇总分析

Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
PubMed 文献 · JAMA Oncol · 2024-01-01

该汇总分析纳入6项临床试验共573例高危可切除黑色素瘤患者,比较新辅助双免疫检查点抑制剂与抗PD1单药的安全性和疗效。双免疫检查点抑制剂与更高的病理完全缓解率相关(OR 3.16,P < .001),但也与更高的3或4级免疫相关不良事件风险相关(OR 3.75,P < .001)。

要点

  • 双免疫检查点抑制剂较抗PD1单药提高病理完全缓解率(OR 3.16,P < .001),但3或4级免疫相关不良事件风险也升高(OR 3.75,P < .001)。
  • 传统剂量伊匹木单抗联合纳武利尤单抗较抗PD1单药提高影像学客观缓解率(OR 1.95,P = .046)和病理完全缓解率(OR 2.99,P < .001)。
  • 替代剂量伊匹木单抗联合纳武利尤单抗较抗PD1单药提高影像学完全缓解率(OR 2.55,P = .03)和病理完全缓解率(OR 3.87,P < .001)。

核心结论

  • 在高危可切除黑色素瘤新辅助治疗中,双免疫检查点抑制剂与更高的病理和影像学缓解可能性相关,但抗PD1单药的3或4级免疫相关不良事件风险显著更低。
  • 与传统剂量伊匹木单抗联合纳武利尤单抗相比,替代剂量方案的3或4级免疫相关不良事件风险增加,但影像学或病理学疗效无显著差异。

研究设计与样本

  • 本汇总分析纳入2018年1月至2023年3月发表的1、2或3期临床试验,研究免疫检查点抑制剂治疗高危可切除黑色素瘤。
  • 共纳入6项临床试验的573例患者,治疗包括抗PD1单药、传统剂量双免疫检查点抑制剂(伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg)或替代剂量双免疫检查点抑制剂(伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg)。

主要发现

  • 双免疫检查点抑制剂较抗PD1单药与更高的病理完全缓解率相关(OR 3.16,P < .001)。
  • 双免疫检查点抑制剂较抗PD1单药与更高的3或4级免疫相关不良事件风险相关(OR 3.75,P < .001)。
  • 传统剂量伊匹木单抗联合纳武利尤单抗较抗PD1单药与更高的影像学客观缓解率相关(OR 1.95,P = .046),与更高的病理完全缓解率相关(OR 2.99,P < .001)。
  • 传统剂量伊匹木单抗联合纳武利尤单抗较抗PD1单药与更高的3或4级免疫相关不良事件风险相关(OR 9.59,P < .001)。
  • 替代剂量伊匹木单抗联合纳武利尤单抗较抗PD1单药与更高的影像学完全缓解率相关(OR 2.55,P = .03)和更高的病理完全缓解率相关(OR 3.87,P < .001),与更高的3或4级免疫相关不良事件风险相关(OR 2.02,P = .02)。

关键数值与推荐

  • 传统剂量伊匹木单抗联合纳武利尤单抗较替代剂量方案与更高的3或4级免疫相关不良事件风险相关(OR 4.76,P < .001)。
  • 传统剂量与替代剂量伊匹木单抗联合纳武利尤单抗在影像学完全缓解、影像学客观缓解、影像学进展或病理完全缓解方面无统计学显著差异。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite the clear potential benefits of neoadjuvant therapy, the optimal neoadjuvant regimen for patients with high-risk resectable melanoma (HRRM) is not known. OBJECTIVE: To compare the safety and efficacy of dual checkpoint inhibitors with anti-programmed cell death protein-1 (anti-PD1) therapy in a neoadjuvant setting among patients with HRRM. DESIGN, SETTING, AND PARTICIPANTS: In this pooled analysis of clinical trials, studies were selected provided they investigated immune checkpoint inhibitor treatment, were published between January 2018 and March 2023, and were phase 1, 2, or 3 clinical trials. Participant data included in the analysis were derived from trials evaluating the efficacy and safety of anti-PD1 monotherapy and the combination of anti-cytotoxic T lymphocyte-associated protein-4 with anti-PD1 in the neoadjuvant setting, specifically among patients with HRRM. INTERVENTIONS: Patients were treated with either anti-PD1 monotherapy; dual checkpoint inhibition (DCPI) with a conventional dose of 3-mg/kg ipilimumab and 1-mg/kg nivolumab; or DCPI with an alternative-dose regimen of 1-mg/kg ipilimumab and 3-mg/kg nivolumab. MAIN OUTCOMES AND MEASURES: The main outcomes were radiologic complete response (rCR), radiologic overall objective response (rOOR), and radiologic progressive disease. Also, pathologic complete response (pCR), the proportion of patients undergoing surgical resection, and occurrence of grade 3 or 4 immune-related adverse events (irAEs) were considered. RESULTS: Among 573 patients enrolled in 6 clinical trials, neoadjuvant therapy with DCPI was associated with higher odds of achieving pCR compared with anti-PD1 monotherapy (odds ratio [OR], 3.16; P < .001). DCPI was associated with higher odds of grade 3 or 4 irAEs compared with anti-PD1 monotherapy (OR, 3.75; P < .001). When comparing the alternative-dose ipilimumab and nivolumab (IPI-NIVO) regimen with conventional-dose IPI-NIVO, no statistically significant difference in rCR, rOOR, radiologic progressive disease, or pCR was noted. However, the conventional-dose IPI-NIVO regimen was associated with increased grade 3 or 4 irAEs (OR, 4.76; P < .001). Conventional-dose IPI-NIVO was associated with greater odds of achieving improved rOOR (OR, 1.95; P = .046) and pCR (OR, 2.99; P < .001) compared with anti-PD1 monotherapy. The alternative dose of IPI-NIVO also was associated with higher odds of achieving rCR (OR, 2.55; P = .03) and pCR (OR, 3.87; P < .001) compared with anti-PD1 monotherapy. The risk for grade 3 or 4 irAEs is higher with both the conventional-dose (OR, 9.59; P < .001) and alternative-dose IPI-NIVO regimens (OR, 2.02; P = .02) compared with anti-PD1 monotherapy. CONCLUSION AND RELEVANCE: In this pooled analysis of 6 clinical trials, although DCPI was associated with increased likelihood of achieving pathological and radiologic responses, the associated risk for grade 3 or 4 irAEs was significantly lower with anti-PD1 monotherapy in the neoadjuvant setting for HRRM. Additionally, compared with alternative-dose IPI-NIVO, the conventional dose of IPI-NIVO was associated with increased risk for grade 3 or 4 irAEs, with no significant distinctions in radiologic or pathologic efficacy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mangla A, Lee C, Mirsky MM, et al. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024. PMID: 38546551. doi:10.1001/jamaoncol.2023.7333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。